It shouldn’t come as any surprise that the world is awash with reports on the omicron COVID variant. That variant, which went public so to speak on Friday, was not received well by the market.
Major equity markets around the globe fell in excess of 2.0% as market participants got caught up thinking the worse. That is, omicron could be more infectious than Delta, lead to more severe disease than Delta, and evade current vaccines. Today, though, the angst has been dialed down a bit and the U.S. market is poised to rebound.
Currently, the S&P 500 futures are up 54 points and are trading 1.2% above fair value, the Nasdaq 100 futures are up 216 points and are trading 1.4% above fair value, and the Dow Jones Industrial Average futures are up 371 points and are trading 1.2% above fair value.
That positive disposition is predicated partly on an embrace of the buy-the-dip trade and partly on the burgeoning hope that omicron can be corralled with current vaccines, current treatments, and/or new vaccine formulations that can be ready relatively soon.
Moderna’s (MRNA) Chief Medical Officer said he thinks a new vaccine targeting omicron could be ready early in 2022 if needed. Shares of MRNA, which soared 21% on Friday, are up another 10% today.
Another tidbit of hope includes reports that health officials in South Africa have said the omicron variant is typically leading to only mild symptoms for those infected with it. Still, the WHO and other medical experts are clarifying that it is still too early to tell just how transmissible and severe the omicron variant is.
Dr. Fauci told the White House it could take approximately two more weeks to get a better read on things, and Moderna’s CEO said it could take approximately 2-6 weeks to get more clarity on whether this variant is more deadly.
Of course, everyone has an opinion whether they are an expert or not. While many countries have barred travel from southern African nations (Japan is banning all foreign travelers starting November 30), the key for the market is that omicron isn’t triggering any global economic shock.
It’s possible that it could, yet the belief in vaccine efficacy is still winning out as an offset to a worst-case scenario of new lockdown measures in the world’s major economies.
Accordingly, we’re seeing some unwinding of Friday’s flight-to-safety trades and Friday’s economic slowdown fears. To that end, the 10-yr note yield is up six basis points to 1.54% and WTI crude futures are up 5.7% to $72.00 per barrel.
On a related note, OPEC+ is delaying the technical meeting it was going to hold today until Wednesday, according to Bloomberg, to give it more time to assess the news of the omicron variant and the coordinated release of oil from strategic petroleum reserves. The OPEC+ ministers meeting is Thursday where it will be decided if OPEC+ is going to boost production quotas, leave them unchanged, or curtail them.
That meeting is one of several important happenings this week. Others include a good bit of Fedspeak, the ISM Manufacturing and Non-Manufacturing reports, and the November Employment Situation Report. In addition, Congress will need to reach an agreement on a new funding resolution to keep the government funded beyond December 3 or risk a shutdown.
It will be a busy week, then, starting today as market participants busy themselves with ruminations about the omicron variant.
Originally Posted on November 29, 2021 – Dialing Back Omicron Angst
Disclosure: Interactive Brokers
Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Briefing.com and is being posted with permission from Briefing.com. The views expressed in this material are solely those of the author and/or Briefing.com and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
In accordance with EU regulation: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.
Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.
Disclosure: Futures Trading
Futures are not suitable for all investors. The amount you may lose may be greater than your initial investment. Before trading futures, please read the CFTC Risk Disclosure. A copy and additional information are available at ibkr.com.